Enosis Therapeutics has collaborated with Swinburne University and the Psychedelic Society of Belgium to carry out the study – finding that the use of virtual reality...
Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
Health Canada has granted approval to Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.
In recent weeks, much has been made of psychedelic drugs’ potential to redefine mental health treatment.
The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) has confirmed it has now fully enroled its Phase III trial of MDMA-assisted therapy for PTSD.
Policy specialists PsychedelicsEUROPE and biopharma company, Mycotopia Therapies, are partnering to explore opportunities for psychedelic care on the continent.
Numinus Wellness is hosting a series of immersive events – Music as Medicine – to highlight the role that music can play in healing.
A Phase II trial is being conducted to investigate the potential of psilocybin-assisted psychotherapy as a treatment for binge eating disorder (BED).
SABI Mind and Reverie Psychedelics have partnered to expand research into psychedelic-assisted therapies.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.